Blockade of AP-1 Potentiates Endocrine Therapy and Overcomes Resistance

by Malorni, Luca, Giuliano, Mario, Migliaccio, Ilenia, Wang, Tao, Creighton, Chad J., Lupien, Mathieu, Fu, Xiaoyong, Hilsenbeck, Susan G., Healy, Nuala, De Angelis, Carmine, Mazumdar, Abhijit, Trivedi, Meghana V., Massarweh, Suleiman, Gutierrez, Carolina, De Placido, Sabino, Jeselsohn, Rinath, Brown, Myles, Brown, Powel H., Osborne, C. Kent, Schiff, Rachel
Published in Mol Cancer Res (2016)

Neratinib plus trastuzumab is superior to pertuzumab plus trastuzumab in HER2-positive breast cancer xenograft models

by Veeraraghavan, Jamunarani, Gutierrez, Carolina, Sethunath, Vidyalakshmi, Mehravaran, Sepideh, Giuliano, Mario, Shea, Martin J., Mitchell, Tamika, Wang, Tao, Nanda, Sarmistha, Pereira, Resel, Davis, Robert, Goutsouliak, Kristina, Qin, Lanfang, De Angelis, Carmine, Diala, Irmina, Lalani, Alshad S., Nagi, Chandandeep, Hilsenbeck, Susan G., Rimawi, Mothaffar F., Osborne, C. Kent, Schiff, Rachel
Published in NPJ Breast Cancer (2021)

Upregulation of ER signaling as an adaptive mechanism of cell survival in HER2-positive breast tumors treated with anti-HER2 therapy

by Giuliano, Mario, Hu, Huizhong, Wang, Yen-Chao, Fu, Xiaoyong, Nardone, Agostina, Herrera, Sabrina, Mao, Sufeng, Contreras, Alejandro, Gutierrez, Carolina, Wang, Tao, Hilsenbeck, Susan G., De Angelis, Carmine, Wang, Nicholas J., Heiser, Laura M., Gray, Joe W., Lopez-Tarruella, Sara, Pavlick, Anne C., Trivedi, Meghana V., Chamness, Gary C., Chang, Jenny C., Osborne, C. Kent, Rimawi, Mothaffar F., Schiff, Rachel
Published in Clin Cancer Res (2015)

FOXA1 upregulation promotes enhancer and transcriptional reprogramming in endocrine-resistant breast cancer

by Fu, Xiaoyong, Pereira, Resel, De Angelis, Carmine, Veeraraghavan, Jamunarani, Nanda, Sarmistha, Qin, Lanfang, Cataldo, Maria L., Sethunath, Vidyalakshmi, Mehravaran, Sepideh, Gutierrez, Carolina, Chamness, Gary C., Feng, Qin, O’Malley, Bert W., Selenica, Pier, Weigelt, Britta, Reis-Filho, Jorge S., Cohen, Ofir, Wagle, Nikhil, Nardone, Agostina, Jeselsohn, Rinath, Brown, Myles, Rimawi, Mothaffar F., Osborne, C. Kent, Schiff, Rachel
Published in Proc Natl Acad Sci U S A (2019)

Evaluation of the predictive role of tumor immune infiltrate in HER2-positive breast cancer patients treated with neoadjuvant anti-HER2 therapy without chemotherapy

by De Angelis, Carmine, Nagi, Chandandeep, Hoyt, Cliff C., Liu, Linying, Roman, Kristin, Wang, Chichung, Zheng, Yi, Veeraraghavan, Jamunarani, Sethunath, Vidyalakshmi, Nuciforo, Paolo, Wang, Tao, Tsimelzon, Anna, Mao, Sufeng, Hilsenbeck, Susan G., Trivedi, Meghana V., Cataldo, Maria Letizia, Pavlick, Anne C., Wolff, Antonio C., Weigelt, Britta, Reis-Filho, Jorge S., Prat, Aleix, Gutierrez, Carolina, Osborne, C. Kent, Rimawi, Mothaffar F., Schiff, Rachel
Published in Clin Cancer Res (2019)

FOXA1 overexpression mediates endocrine resistance by altering the ER transcriptome and IL-8 expression in ER-positive breast cancer

by Fu, Xiaoyong, Jeselsohn, Rinath, Pereira, Resel, Hollingsworth, Emporia F., Creighton, Chad J., Li, Fugen, Shea, Martin, Nardone, Agostina, De Angelis, Carmine, Heiser, Laura M., Anur, Pavana, Wang, Nicholas, Grasso, Catherine S., Spellman, Paul T., Griffith, Obi L., Tsimelzon, Anna, Gutierrez, Carolina, Huang, Shixia, Edwards, Dean P., Trivedi, Meghana V., Rimawi, Mothaffar F., Lopez-Terrada, Dolores, Hilsenbeck, Susan G., Gray, Joe W., Brown, Myles, Osborne, C. Kent, Schiff, Rachel
Published in Proc Natl Acad Sci U S A (2016)

Low PTEN Levels and PIK3CA Mutations Predict Resistance to Neoadjuvant Lapatinib and Trastuzumab without Chemotherapy in Patients with HER2 Over-Expressing Breast Cancer

by Rimawi, Mothaffar F., De Angelis, Carmine, Contreras, Alejandro, Pareja, Fresia, Geyer, Felipe C., Burke, Kathleen A., Herrera, Sabrina, Wang, Tao, Mayer, Ingrid A, Forero, Andres, Nanda, Rita, Goetz, Matthew P., Chang, Jenny C., Krop, Ian E., Wolff, Antonio C., Pavlick, Anne C., Fuqua, Suzanne A. W., Gutierrez, Carolina, Hilsenbeck, Susan G., Li, Marilyn M., Weigelt, Britta, Reis-Filho, Jorge S., Osborne, C. Kent, Schiff, Rachel
Published in Breast Cancer Res Treat (2017)

HER2-Enriched Subtype and ERBB2 Expression in HER2-Positive Breast Cancer Treated with Dual HER2 Blockade

by Prat, Aleix, Pascual, Tomás, De Angelis, Carmine, Gutierrez, Carolina, Llombart-Cussac, Antonio, Wang, Tao, Cortés, Javier, Rexer, Brent, Paré, Laia, Forero, Andres, Wolff, Antonio C, Morales, Serafín, Adamo, Barbara, Brasó-Maristany, Fara, Vidal, Maria, Veeraraghavan, Jamunarani, Krop, Ian, Galván, Patricia, Pavlick, Anne C, Bermejo, Begoña, Izquierdo, Miguel, Rodrik-Outmezguine, Vanessa, Reis-Filho, Jorge S, Hilsenbeck, Susan G, Oliveira, Mafalda, Dieci, Maria Vittoria, Griguolo, Gaia, Fasani, Roberta, Nuciforo, Paolo, Parker, Joel S, Conte, PierFranco, Schiff, Rachel, Guarneri, Valentina, Osborne, C Kent, Rimawi, Mothaffar F
Published in J Natl Cancer Inst (2019)

HER2 Reactivation through Acquisition of the HER2 L755S Mutation as a Mechanism of Acquired Resistance to HER2-targeted Therapy in HER2+ Breast Cancer

by Xu, Xiaowei, De Angelis, Carmine, Burke, Kathleen A., Nardone, Agostina, Hu, Huizhong, Qin, Lanfang, Veeraraghavan, Jamunarani, Sethunath, Vidyalakshmi, Heiser, Laura M., Wang, Nicholas, Ng, Charlotte K.Y., Chen, Edward S., Renwick, Alexander, Wang, Tao, Nanda, Sarmistha, Shea, Martin, Mitchell, Tamika, Rajendran, Mahitha, Waters, Ian, Zabransky, Daniel J., Scott, Kenneth L., Gutierrez, Carolina, Nagi, Chandandeep, Geyer, Felipe C., Chamness, Gary C., Park, Ben H., Shaw, Chad A., Hilsenbeck, Susan G., Rimawi, Mothaffar F., Gray, Joe W., Weigelt, Britta, Reis-Filho, Jorge S., Osborne, C. Kent, Schiff, Rachel
Published in Clin Cancer Res (2017)